# Research timeline and gaps: Berberine and Glycemic Control

Selected publication milestones, not an exhaustive history or discovery priority claim.

**2006 — Human cyclosporin interaction work shows dose-dependent exposure effects, an early constraint on simple supplement-safety claims.** [Original PMID16541194](https://pubmed.ncbi.nlm.nih.gov/16541194/).

**2008 — A three-month placebo-controlled T2D/dyslipidemia trial reports HbA1c and glucose benefit with ordinary berberine.** [Original PMID18397984](https://pubmed.ncbi.nlm.nih.gov/18397984/).

**2008 — The metformin pilot and uncontrolled add-on component motivate clinical research while leaving noninferiority and treatment attribution unresolved.** [Original PMID18442638](https://pubmed.ncbi.nlm.nih.gov/18442638/).

**2008 — Acute secretion inhibition and later cell response show that dose, glucose state and timing matter for mechanism narratives.** [Original PMID18511510](https://pubmed.ncbi.nlm.nih.gov/18511510/).

**2010 — Patient metabolomics proposes free-fatty-acid involvement but is conservatively grouped with related earlier efficacy work.** [Original PMID20298851](https://pubmed.ncbi.nlm.nih.gov/20298851/).

**2012 — Repeated-dose healthy-human CYP probe testing verifies drug-interaction potential rather than assuming inert supplement exposure.** [Original PMID21870106](https://pubmed.ncbi.nlm.nih.gov/21870106/).

**2015 — A direct glutathione trial establishes body-store engagement, providing ingredient context without testing a triple stack.** [Original PMID24791752](https://pubmed.ncbi.nlm.nih.gov/24791752/).

**2015 — Animal microbial conversion/absorption experiments propose an exposure route; broad antibiotic perturbation does not isolate clinical human mediation.** [Original PMID26174047](https://pubmed.ncbi.nlm.nih.gov/26174047/).

**2020 — PREMOTE supplies a verified concealed twelve-week T2D placebo comparison and a separate microbial hypothesis under common antibiotic pretreatment.** [Original PMID33024120](https://pubmed.ncbi.nlm.nih.gov/33024120/).

**2021 — NMN improves measured muscle insulin sensitivity in prediabetic women, a component-specific result without combination evidence.** [Original PMID33888596](https://pubmed.ncbi.nlm.nih.gov/33888596/).

**2021 — Mouse KCNH6 loss and a healthy-human acute clamp narrow a secretion mechanism; the attached correction changes an author name only.** [Original PMID34556670](https://pubmed.ncbi.nlm.nih.gov/34556670/).

**2022 — A PREMOTE lipid secondary analysis illustrates why new mechanistic resolution is not a new independent efficacy trial.** [Original PMID34923903](https://pubmed.ncbi.nlm.nih.gov/34923903/).

**2023 — Short NMN physiology produces NAD and selected risk-factor changes while several functional/metabolic endpoints remain null.** [Original PMID36740954](https://pubmed.ncbi.nlm.nih.gov/36740954/).

**2024 — An older-adult NMN trial has a null primary stepping endpoint alongside selected secondary walking/sleep signals.** [Original PMID38789831](https://pubmed.ncbi.nlm.nih.gov/38789831/).

**2025 — A distinct BUDCA formulation produces dose-related twelve-week T2D HbA1c benefit while weight stays stable.** [Original PMID40029660](https://pubmed.ncbi.nlm.nih.gov/40029660/).

**2026 — A six-month ordinary-berberine obesity/MASLD trial is null for adiposity and glycemic measures in diabetes-free adults, limiting broad weight-loss extrapolation.** [Original PMID41543854](https://pubmed.ncbi.nlm.nih.gov/41543854/).

**2026 — Drug-response signature MR generates cardiometabolic hypotheses without directly instrumenting oral exposure or replacing clinical event trials.** [Original PMID41882153](https://pubmed.ncbi.nlm.nih.gov/41882153/).

## Research gaps

Durable ordinary-berberine efficacy and safety beyond short T2D trials under contemporary unchanged standard care

Role of common antibiotic pretreatment and baseline microbial ecology in the PREMOTE response

Exposure/product standardization and translation between ordinary berberine, BUDCA and botanical bundles

Unique chronic human mediation versus simultaneous gut, secretion, receptor and mitochondrial effects

Direct modern GLP-1 equivalence for specified weight and cardiometabolic outcomes

Exact triple-stack trials and component-dismantling evidence with meaningful functional outcomes

Drug interactions, formulation variability and all-comer tolerability beyond selected short-term cohorts

## Boundary experiment

Run a multisite, baseline-stratified, double-blind trial of chemically verified ordinary oral berberine versus matching placebo added to unchanged standard T2D care, with prespecified twelve-month glycemic durability and adverse-event outcomes. Include strata for baseline HbA1c, disease duration and fixed co-medication; avoid routine antibiotic pretreatment or randomize that factor separately if mechanistically essential. Add prespecified pathway measurements and an orthogonal mediator-dissociation component rather than declaring correlated microbiome changes necessary. Evaluate GLP-1 equivalence and the exact triple stack in separate properly controlled trials.